Clinical Trial Search

Primary: Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo — 432.6; 400.5; 4477.5; 490.6 geometric mean titer

Primary: Time to Last Unformed Stool (TLUS) — 37.4; 21.; 68; 46 TLUS (hours)

Primary: Cumulative Occurrence of Travellers' Diarrhea (TD) for Rifaximin 600 mg QD Compared to Placebo Over 14 Days of Treatment — 15; 48 Participants

Primary: Characterization and Comparison of the Safety of the TD Vaccine System: (1) Solicited and Unsolicited Adverse Events (AEs) (2) Clinical Laboratory Safety (3) Serious AEs…

Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours

Primary: Incidence of Adverse Events — 1; 1; 0; 1 events

Primary: Safety of Serum Derived Bovine Immunoglobulins (BSIgG) — 1; 2; 0; 2 Participants

Primary: Part A: Number of Serious Adverse Events and Adverse Events Leading to Withdrawal — 0; 0; 0; 0 adverse events

Primary: Number of Participants Who Achieved Clinical Cure at Test of Cure (TOC) Visit (Within 24 to 72 Hours From the Time of Last Dose): Per-Protocol (PP) Population — 90; 93…

Primary: Number of Participants With Moderate and Severe Diarrhea — 17 participants moderate or severe diarrea

Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003

Primary: Duration of Diarrhea in Acute Diarrheal Illnesses in a Developed Nation While Taking Zinc or Placebo. — 73; 72; 48; 76.8 Hours — p=0.88

Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc

Primary: Maximum Severity of Reactogenicity by Vaccination — 1; 0; 0; 0 Participants

Primary: Time to Last Unformed Stool (TLUS) — 59.3; 51.4; 57.4 hours

Primary: Duration of Diarrhea — 2; 2 days — p=0.43

Primary: Diarrheal Stool Output Rate — 25.42; 32.57 mL/hour — p=0.2254

Primary: Number of Participants With Post Infectious Irritable Bowel Syndrome — 23; 114 participants

Primary: Presence of AAD — 12 participants — p=<0.05

Primary: Diarrhea for >= 2 Consecutive Days — 68; 69.6; 65.2; 72.2 percentage of patients

Primary: Campylobacteriosis — 13; 11 Participants

Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants

Primary: Number and Percentage of Participants With Serious Adverse Events (SAEs) — 0; 0; 1; 0 Participants

Primary: Stool Output — 4769; 4742; 1688; 1704 gram — p=0.9941

Primary: Maximum Reactogenicity Per Subject and Treatment Group — 5; 12; 9; 11 Participants

Primary: Safety - Occurrence of Adverse Events — 7; 21; 19; 20 Number of Adverse Events

Primary: Number of Participants With Solicited or Unsolicited Adverse Events — 15; 16; 17; 16 Participants

Primary: Safety as Assessed by Number of Participants With Any Adverse Events (AE)s — 4; 4 Participants — p=0.8958

Primary: Number of Participants With Solicited Administration-site Events After the First Vaccination — 3; 11; 20; 22 Participants

Primary: Number and Percentage of Participants Experiencing Solicited Events by Symptom and Maximum Severity — 15; 14; 15; 15 Participants